Companies: 10,795·Total market cap: $144.5T
Akero Therapeutics, Inc.

Akero Therapeutics, Inc.

AKRONASDAQHealthcare
$54.65
+$0.00(+0.00%)
Market Cap$4.5B
P/E Ratio—
52W High$58.4
52W Low$21.34
SEC Filings

Akero Therapeutics, Inc. (AKRO) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001744659 · AKRO · NASDAQ · as of Jun 8, 2026

Filing snapshot

734
Total Filings
SCHEDULE 13G/A
Latest Form
2026-02-17
Most Recent
2019
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001744659 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2025-02-28
Fiscal Year End
Feb 28, 2025
Accession No.
0000950170-25-029514
Primary Document
akro-20241231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001744659 · Accession 0000950170-25-029514

Latest Key Filings

10-QQuarterly Report
10-Q
2025-11-07
View 10-Q on SEC
8-KCurrent Report
8-K
2025-12-09Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-13
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-10
View
15-12G15-12G
15-12G
2025-12-19
View
25-NSE25-NSE
25-NSE
2025-12-09
View
S-8 POSS-8 POS
S-8 POS
2025-12-09
View
S-8 POSS-8 POS
S-8 POS
2025-12-09
View
S-8 POSS-8 POS
S-8 POS
2025-12-09
View
S-8 POSS-8 POS
S-8 POS
2025-12-09
View
S-8 POSS-8 POS
S-8 POS
2025-12-09
View
S-8 POSS-8 POS
S-8 POS
2025-12-09
View
S-8 POSS-8 POS
S-8 POS
2025-12-09
View
POSASRPOSASR
POSASR
2025-12-09
View
8-KCurrent Report
8-K
2025-12-09
View
Showing 1–15 of 284 filingsForm 4 / 144 hidden· 734 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001744659  |  Exchange: NASDAQ · Healthcare

Akero Therapeutics, Inc. (NASDAQ: AKRO) has submitted 734 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2019. As a Healthcare sector company with CIK 0001744659, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Akero Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Akero Therapeutics, Inc. 10-K was filed on 2025-02-28 for fiscal year ending 2025. Historical AKRO 10-K annual reports are available from 2018 through 2025.

Investors researching Akero Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
ACLX SEC Filings →IMVT SEC Filings →CNTA SEC Filings →KYMR SEC Filings →PRAX SEC Filings →ACAD SEC Filings →NAMS SEC Filings →CRNX SEC Filings →
→ AKRO Financials→ AKRO Earnings→ AKRO Insider Trades

Frequently Asked Questions

AKRO SEC Filings · 8 questions

Akero Therapeutics, Inc. (AKRO) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 734 filings and access original documents at no cost. Akero Therapeutics, Inc.'s CIK is 0001744659.

AKRO SEC filingsAkero Therapeutics, Inc. SEC documentsfind AKRO 10-K